Evidence map›Paper›PMID 20106982›Full record

ArticleThe Journal of biological chemistry2010

CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Yihong Ma, Lu Chen, Gabriela M Wright, Smitha R Pillai, Srikumar P Chellappan, W Douglas Cress

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Adrenocortical stem cells in health and disease.Nature reviews. Endocrinology · 2025
    Review
  2. Microcephaly GeneInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57Frontiers in cell and developmental biology · 2021
    Article
  5. The CDK inhibitor p57Scientific reports · 2020
    Article
  6. Functional Versatility of the CDK Inhibitor p57Frontiers in cell and developmental biology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yihong MaMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
Lu ChenMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
Gabriela M WrightMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
Smitha R PillaiMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
Srikumar P ChellappanMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.
W Douglas CressMolecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612. Electronic address: douglas.cress@moffitt.org.
Molecular Oncology (United States) · USMoffitt Cancer Center · US

Funding

SPORE in Lung CancerP50CA119997 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GABRILOVICH, DMITRY I · 2008 to 2012
$11.0M
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1R01CA090489 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI CRESS, WILLIAM D · 2003 to 2007
$1.6M
NCI NIH HHS CA119997NCI NIH HHS CA90489NCI NIH HHS P50 CA119997NCI NIH HHS R01 CA090489
6 · The paper itself

Abstract

CDKN1C is a cyclin-dependent kinase inhibitor and is a candidate tumor suppressor gene. We previously found that the CDKN1C protein represses E2F1-driven transcription in an apparent negative feedback loop. Herein, we explore the mechanism by which CDKN1C represses transcription. We find that adenoviral-mediated overexpression of CDKN1C leads to a dramatic reduction in phosphorylation of the RNA polymerase II (pol II) C-terminal domain (CTD). RNA interference studies demonstrate that this activity is not an artifact of CDKN1C overexpression, because endogenous CDKN1C mediates an inhibition of RNA pol II CTD phosphorylation in HeLa cells upon treatment with dexamethasone. Surprisingly, we find that CDKN1C-mediated repression of RNA pol II phosphorylation is E2F1-dependent, suggesting that E2F1 may direct CDKN1C to chromatin. Chromatin immunoprecipitation assays demonstrate that CDKN1C is associated with E2F1-regulated promoters in vivo and that this association can dramatically reduce the level of RNA pol II CTD phosphorylation at both Ser-2 and Ser-5 of the C-terminal domain repeat. In addition, we show that CDKN1C interacts with both CDK7 and CDK9 (putative RNA pol II CTD kinases) and that CDKN1C blocks their ability to phosphorylate a glutathione S-transferase-CTD fusion protein in vitro. E2F1 and CDKN1C are found to form stable complexes both in vivo and in vitro. Molecular studies demonstrate that the E2F1-CDKN1C interaction is mediated by two E2F domains. A central E2F1 domain interacts directly with CDKN1C, whereas a C-terminal E2F1 domain interacts with CDKN1C via interaction with Rb. The results presented in this report highlight a novel mechanism of tumor suppression by CDKN1C.

Indexed as

Gene Expression Regulation, EnzymologicCell CycleCell Line, TumorChromatin ImmunoprecipitationCyclin-Dependent Kinase Inhibitor p57E2F1 Transcription FactorHeLa CellsHumansModels, BiologicalPhosphorylationPromoter Regions, GeneticProtein Structure, TertiaryRNA Polymerase IITranscription, GeneticCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57E2F1 Transcription FactorRNA Polymerase II

Identifiers

PMID20106982
PMCPMC2843230
OpenAlexW1967731271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.